Cardarine is a PPAR-delta agonist widely discussed in endurance and metabolic research, often grouped alongside SARMs in the community. Below, we compare vendors currently stocking research-grade Cardarine — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 ChemyoBest Value |
$59.99 (10mg/ml solution) | Third-party COA | Buy Here → | |
 MuscleChem |
£49.99 | In-house testing | Buy Here → | |
 SwissChems |
$69.95 | Third-party COA | Buy Here → | |
 Next Chem |
$69.96 (liquid solution) | Third-party COA | Auto-applied | Buy Here → |
Cardarine (GW-501516) is a synthetic PPAR-delta (PPARδ) receptor agonist originally developed by GlaxoSmithKline and Ligand Pharmaceuticals in the 1990s-2000s for research into metabolic conditions such as dyslipidemia and obesity. It is not a SARM despite frequently being marketed alongside them, since it does not act on the androgen receptor at all.
Research-grade Cardarine is typically supplied as a liquid solution or capsules, commonly at 10mg/mL or 10mg per capsule, intended for laboratory research use only.
Cardarine activates PPAR-delta, a nuclear receptor that regulates genes involved in fatty-acid metabolism and energy expenditure, shifting cellular metabolism toward fat oxidation — the mechanism behind its research interest in endurance and metabolic contexts.
Preclinical studies found that Cardarine increased fat oxidation and endurance capacity in animal models, and it was originally studied by its developers specifically for metabolic syndrome and dyslipidemia before that program was discontinued.
The original GSK/Ligand clinical development program for Cardarine was discontinued after long-term carcinogenicity studies in animals showed rapid-onset cancers across multiple organs at exposure levels relevant to the studied doses — a well-documented reason the compound never advanced to human approval and remains a significant safety consideration in any Cardarine research discussion.
Because of the carcinogenicity findings that ended its original development program, Cardarine carries a materially different risk profile from other research compounds in this category. It has never been approved for human use, has no established human safety data from completed trials, and is banned by the World Anti-Doping Agency.
No FDA-approved or clinically validated human dosage exists for Cardarine. Doses referenced in early-stage human trials before program discontinuation are documented in that limited trial literature but do not constitute an established protocol.
Compound X does not sell Cardarine (GW-501516) directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Cardarine's preclinical and toxicology findings are indexed on PubMed under "GW501516 PPAR delta carcinogenicity" and "Cardarine GW-501516 metabolic."
New guides, vendor comparisons and compound breakdowns every week.